NCT07285304

A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

A Phase 3 Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.

Conditions

• Hyperphosphatemia Patients on Hemodialysis

Interventions

Type	Name	Description
DRUG	TS-172	oral administration of TS-172 20\~60 mg/day

Timeline

• Start date: 2025-12-01
• Primary completion: 2027-07-31
• Completion: 2027-07-31
• First posted: 2025-12-16
• Last updated: 2025-12-16

Locations

1 site across 1 country: Japan